^
Association details:
| Biomarker: | TERT promoter mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Published date:
12/08/2023
Excerpt:
The ORRs of pembrolizumab were 21% and 71% in patients with or without TERT promoter mutations, respectively (p<0.001)….Our analysis suggests that the presence of TERT promoter mutations could negatively affect the outcome of UC patients treated by chemotherapy or pembrolizumab.
DOI:
https://doi.org/10.1016/j.prp.2023.155008
